Myriad Genetics (NASDAQ:MYGN) was upgraded by equities research analysts at Ladenburg Thalmann from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $28.00 price objective on the stock. Ladenburg Thalmann’s target price points to a potential upside of 10.63% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Ned Davis Research downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Friday, August 16th. They now have a $29.00 price target on the stock. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.00.
Shares of Myriad Genetics (NASDAQ:MYGN) traded down 1.07% on Tuesday, hitting $25.04. 268,577 shares of the company’s stock traded hands. Myriad Genetics has a 52 week low of $22.61 and a 52 week high of $38.27. The stock’s 50-day moving average is $26.71 and its 200-day moving average is $28.44. The company has a market cap of $2.014 billion and a price-to-earnings ratio of 14.30. Myriad Genetics also was the target of some unusual options trading on Monday. Traders purchased 11,342 put options on the company. This represents an increase of 365% compared to the average daily volume of 2,438 put options.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 13th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.